DATE: September 25, 1997

MEMORANDUM


FROM: Jess Rowland  
Branch Senior Scientist,
Science Analysis Branch, Health Effects Division (7509C)

THROUGH: K. Clark Swentzel  
Chairman, Hazard Identification Assessment Review Committee
Toxicology Branch II, Health Effects Division (7509C)

TO: Mike Metzger 
Reregistration Branch 2
Health Effects Division (7509C)

BACKGROUND: On September 8, 1997, the Health Effects Division's Hazard Identification Assessment Review Committee met to evaluate the toxicology data base of Profenofos with special reference to the reproductive, developmental and neurotoxicity data. These data were re-reviewed specifically to address the sensitivity of infants and children from exposure to Profenofos as required by the Food Quality Protecting Act (FQPA) of 1996. The FQPA requirement was not addressed in the Reregistration Eligibility Document. The Committee's decisions are summarized below.

CC: Rick Whiting, Science Analysis Branch
Caswell File
LAN storage
A. INTRODUCTION

The Health Effects Division's Hazard Identification Assessment Review Committee met to evaluate the toxicology data base of Profenofos with special reference to the reproductive, developmental and neurotoxicity data. These data were re-reviewed specifically to address the sensitivity of infants and children from exposure to Profenofos as required by the Food Quality Protecting Act (FQPA) of 1996. The FQPA requirement was not addressed in the Reregistration Eligibility Document.

B. RESULTS:

1. Neurotoxicity

- In an acute delayed neurotoxicity study in hens with a formulation (38% a.i), no neurotoxicity was seen at dose levels up to 52 mg/kg, with 100% mortality at next highest dose level of 104 mg/kg. Negative results for delayed neurotoxicity were also reported in two supplementary studies with the technical product. The Committee noted that these studies did not assess for the potential of Profenofos to inhibit neurotoxic esterase (NTE) in hens (MRID Nos. 00082083, 00082085, 00097797).

- In an acute neurotoxicity study, Sprague-Dawley rats (10/sex/dose) were given a single oral administration of Profenofos in corn oil at 0, 95, 190 or 380 mg/kg/day. Neurotoxicity was seen only at the time of peak effect. For neurotoxicity, the NOEL was 95 mg/kg and the LOEL was 190 mg/kg based on an increased incidence of staining of the nose and compulsive licking (stereotypy) in males and an increased incidence of diarrhea, miosis, staining of the nose, abnormal gait, and ease of handling. For cholinesterase inhibition, the LOEL was 95 mg/kg (LDT) based on a dose-related inhibition of plasma and red blood cell cholinesterase activities seen in both sexes; a NOEL was not established. Brain cholinesterase activity was unaffected in both sexes (MRID No. 42939801).

- In a subchronic neurotoxicity study, Sprague-Dawley rats (10/sex/dose) were fed diets containing Profenofos at 0, 30, 135 or 600 ppm (0, 1.7, 7.7 or 36 mg/kg/day in males and 1.84, 8.4 or 37.9 mg/kg/day in females, respectively) for 13 weeks. No treatment-related neurotoxicity or pathological lesions of the central or peripheral nervous system were observed. For neurotoxicity, the NOEL was >36 mg/kg/day (HDT); a LOEL was not established. For plasma and red blood cell ChEI, the LOEL was 1.7 mg/kg/day (LDT); a NOEL was not established. For brain ChEI, the NOEL was 7.7 mg/kg/day and the LOEL was 36 mg/kg/day (MRID Nos. 43213303 and 43213304).
2. Developmental Toxicity

- The developmental toxicity studies in rats and rabbits showed no evidence of additional sensitivity to young rats or rabbits following pre- or postnatal exposure to Profenofos and comparable NOELs were established for adults and offspring.

- In a developmental toxicity study pregnant Sprague-Dawley rats received oral doses of Profenofos in carboxymethylcellulose at 0, 10, 30 or 60 mg/kg/day during gestation days 6 through 15. For maternal toxicity, the NOEL was 30 mg/kg/day and the LOEL was 60 mg/kg/day based on decreased food consumption and slightly decreased body weight gain. No developmental toxicity was seen. For developmental toxicity, the NOEL was 60 mg/kg/day (HDT); a LOEL was not established (MRID No. 00045031).

- In a developmental toxicity study, pregnant New Zealand White rabbits were given a single oral dose of Profenofos 0, 30, 60, 90 or 175 mg/kg/day during gestation day 6. For maternal toxicity, the NOEL was 30 mg/kg/day and the LOEL was 60 mg/kg/day based on decreased body weight gain. No developmental toxicity was seen. For developmental toxicity, the NOEL was 175 mg/kg/day (HDT). Although the animals were dosed only on gestation day 6, the RfD Committee concluded that the dose levels used in this study were equal to or higher than the doses that elicited cholinesterase inhibition in other studies (MRID No. 00128870).

3. Reproductive Toxicity

- In a two-generation reproduction study, when administered in the diet at 0, 5, 100 or 400 ppm, to Crl:CD (SD) BR VAF/Plus rats, no increased sensitivity to pups compared to the adults was seen. For parental systemic toxicity, the NOEL was 100 ppm (7.3 mg/kg/day) and the LOEL was 400 ppm (29 mg/kg/day) based on decreased body weight gains in males and females of both the F₀ and F₁ generations at all time period throughout the study and decreased food consumption. For reproductive toxicity, the NOEL was 100 ppm (7.3 mg/kg/day) and the LOEL was 400 ppm (29 mg/kg/day) based on decreased pup body weight in both sexes of F₁ and F₂ litters and cumulative body weight gain on days 14 and 21 of lactation (MRID Nos. 43213308 and 43213309).

4. Cholinesterase Inhibition

- Cholinesterase activity was not measured in the adults and offspring either in the developmental (rats and rabbits) or the reproductive toxicity studies. Therefore, no comparisons could be made for this endpoint between adults and offspring.
5. Developmental Neurotoxicity

- There are sufficient data available to adequately assess the potential for toxicity to young animals following pre-and/or post-natal exposure to Profenofos. These include acceptable developmental toxicity studies in rats and rabbits and a 2-generation reproduction study in rats. In addition, no treatment-related neuropathology was seen in studies conducted in hens or rats. Therefore, based upon a weight-of-the-evidence consideration of the data base, the Committee determined that a developmental neurotoxicity study is not required.

6. Reference Dose (RfD)

- An RfD of 0.00005 mg/kg/day was derived from the NOEL of 0.005 mg/kg/day and an Uncertainty Factor (UF) of 100. The LOEL was based on plasma and red blood cell ChE of observed at 0.05 mg/kg/day in dogs. The UF of 100 included a 10 for intra-species and 10 for inter-species variation.

C. CONCLUSIONS

The Committee's conclusions on the Uncertainty Factors for acute and chronic dietary risk assessments are as follows:

1. Acute Dietary Risk Assessment

The endpoint selected for acute dietary risk assessment is based on the NOEL of 0.5 mg/kg/day for inhibition of cholinesterase activity of plasma (males) and red blood cell (females) in rats at 25 mg/kg/day in rats. For inhibition of brain cholinesterase inhibition, the NOEL was 25 mg/kg/day and the LOEL was 100 mg/kg/day. When the dose selected is from an animal study, usually a UF of 100 would be applied for inter and intra species variability. In this case, however, the Toxicology Endpoint Selection Committee determined that a Margin of Exposure of 10 is adequate because of the comparison between the doses of Profenofos eliciting plasma and red blood cell ChE (25 mg/kg/day) and the much higher dose (100 mg/kg/day) required to cause brain ChE which is of greater toxicological concern.

For acute dietary risk assessment, the Committee determined that the 10 x factor to account for enhanced sensitivity of infants and children (as required by FQPA) should be removed. A Margin of Exposure of 10 is adequate to ensure protection of this population from acute exposure to Profenofos for reasons stated below:

(i) No increased sensitivity to fetuses as compared to maternal animals following an acute in utero exposure in developmental toxicity studies.
(ii) No increased sensitivity to pups as compared to adults in a multi-generation reproduction study in rats.
2. Chronic Dietary Risk Assessment

The endpoint for chronic dietary risk assessment is based on the plasma and red blood cell cholinesterase inhibition observed at 0.05 mg/kg/day (LOEL) in a six moth dog study. The NOEL was 0.005 mg/kg/day. An UF of 100 applied to the NOEL; 10 x each for inter and intra species variability. Thus an RfD of 0.00005 mg/kg/day was derived.

For chronic dietary risk assessment, the Committee determined that the 10 x factor to account for enhanced sensitivity of infants and children (as required by FQPA) should be removed. The present UF of 100 is adequate to ensure protection of this population from chronic exposure to Profenofos. Thus the RfD remains at 0.00005 mg/kg/day. There was not indication of increased sensitivity to young animals following pre-and/or post-natal exposure to Profenofos as shown below:

(i) Developmental toxicity studies showed no increased sensitivity to fetuses as compared to maternal animals following in utero exposures in rats and rabbits.

(ii) A multi generations reproduction toxicity study in rats showed no increased sensitivity to pups as compared to adults.